A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Rutgers, The State University of New Jersey
University of Southern California
Trishula Therapeutics, Inc.
Ohio State University Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)
OHSU Knight Cancer Institute
Sichuan Cancer Hospital and Research Institute
Emory University
AIDS Malignancy Consortium
Virginia Commonwealth University
University of California, San Francisco
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)